DrugPatentWatch Database Preview
APRACLONIDINE HYDROCHLORIDE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Apraclonidine Hydrochloride patents expire, and what generic alternatives are available?
The generic ingredient in APRACLONIDINE HYDROCHLORIDE is apraclonidine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apraclonidine hydrochloride profile page.
Summary for APRACLONIDINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 55 |
| Clinical Trials: | 1 |
| Patent Applications: | 183 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APRACLONIDINE HYDROCHLORIDE |
| DailyMed Link: | APRACLONIDINE HYDROCHLORIDE at DailyMed |
Pharmacology for APRACLONIDINE HYDROCHLORIDE
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Synonyms for APRACLONIDINE HYDROCHLORIDE
| 1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-, monohydrochloride |
| 1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-2-imidazolidinylidene-, monohydrochloride |
| 2-((4-Amino-2,6-dichlorophenyl)imino)imidazolidine monohydrochloride |
| 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride |
| 2-(4-Amino-2,6-dichlorophenylimino)imidazolidine hydrochloride |
| 2-[(2,6-dichloro-4-aminophenyl)imino]imidazolidine hydrochloride |
| 2,6-bis(chloranyl)-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
| 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
| 2,6-Dichloro-N(1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride |
| 2,6-Dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride |
| 2,6-Dichloro-N(sup 1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride |
| 2,6-Dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride |
| 2,6-Dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine Hydrochloride |
| 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
| 218A798 |
| 3,5-Dichloro-4-(2-imidazolidinylidenimino)aniline hydrochloride |
| 4CH-016312 |
| 73218-79-8 |
| 87913-86-8 |
| A 0779 |
| A837749 |
| AC-12705 |
| AC1L1BOD |
| AK143283 |
| AKOS022175501 |
| AKOS025401362 |
| AL 02145 |
| AL-02145 |
| ALO-2145 |
| AN-6532 |
| Aplonidine HCl |
| Aplonidine hydrochloride |
| Apraclonidine hydrochloride |
| Apraclonidine HCl |
| Apraclonidine hydrochloride (JAN/USP) |
| Apraclonidine hydrochloride [USAN] |
| Apraclonidinehydrochloride |
| BG0575 |
| C-17735 |
| C9H10Cl2N4.HCl |
| C9H11Cl3N4 |
| CAS-73218-79-8 |
| CC-24163 |
| CCG-221337 |
| CHEBI:2789 |
| CHEMBL1200379 |
| CTK8F7806 |
| D01008 |
| D2VW67N38H |
| DR000985 |
| DSSTox_CID_25749 |
| DSSTox_GSID_45749 |
| DSSTox_RID_81093 |
| DTXSID6045749 |
| EU-0100033 |
| FT-0602878 |
| Iopidine ophthalmic solution |
| KS-00000MLM |
| LP00033 |
| LS-29586 |
| MFCD00135922 |
| MLS000028829 |
| MLS006010230 |
| MolPort-006-069-427 |
| NC 14 hydrochloride |
| NCGC00093552-01 |
| NCGC00260718-01 |
| OTQYGBJVDRBCHC-UHFFFAOYSA-N |
| p-Aminoclonidine hydrochloride |
| p-Aminoclonidine hydrochloride, solid |
| p-Aminoclonidine Monohydrochloride |
| S311 |
| SCHEMBL41138 |
| SMR000058965 |
| SR-01000075247 |
| SR-01000075247-1 |
| ST2409192 |
| Tox21_111207 |
| Tox21_500033 |
| UNII-D2VW67N38H |
US Patents and Regulatory Information for APRACLONIDINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akorn Inc | APRACLONIDINE HYDROCHLORIDE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 077764-001 | Mar 12, 2009 | AT | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
